Last reviewed · How we verify

NCT03998098

A Single Center Study to Demonstrate the Safety and Performance of Lifelight® First Software Application

Completed Last updated 26 July 2021
What this trial tests

trial testing Oxygen Saturation (Oximetry) in Vital Signs in 85 participants. Completed in 1 May 2021.

Timeline
29 April 2019
Primary endpoint
1 May 2021
1 May 2021

Quick facts

Lead sponsorXim Limited
StatusCompleted
Study typeOBSERVATIONAL
Enrollment85
Start date29 April 2019
Primary completion1 May 2021
Estimated completion1 May 2021
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Xim Limited

Who can join

18 and older, any sex, with Vital Signs. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study validates Lifelight® First, a software application, in a laboratory setting. Participants will undergo testing to obtain measurements from one or more of the four vital signs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Measurement of Vital Signs Using Lifelight Remote Photoplethysmography: Results of the VISION-D and VISION-V Observational Studies.
    Heiden E, Jones T, Brogaard Maczka A, Kapoor M, et al · · 2022 · cited 9× · PMID 36374541 · DOI 10.2196/36340

Verify or expand the search:

Other recruiting trials for Vital Signs

Currently open trials in the same condition.

Other Xim Limited trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03998098.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing